Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

Bujko, Krzysztof; Wyrwicz, Lucjan; Rutkowski, A.; Malinowska, Małgorzata; Pietrzak, L.; Kryński, J; Michalski, Wojciech; Olędzki, Janusz; Kuśnierz, Jerzy; Zajâc, Leszek; Bednarczyk, M.; Szczepkowski, Marek; Tarnowski, Wiesław; Kosakowska, Ewa; Zwoliński, Jakub; Winiarek, M.; Wiśniowska, Katarzyna; Partycki, M.; Bęczkowska, K.; Polkowski, Wojciech; Styliński, Roman; Wierzbicki, Ryszard; Bury, Paweł; Jankiewicz, M.; Paprota, Krzysztof; Lewicka, Magdalena; Ciseł, Bogumiła; Skórzewska, Magdalena; Mielko, Jerzy; Bębenek, Marek; Maciejczyk, Adam; Kapturkiewicz, Bartosz; Dybko, A.; Hajac, Łukasz; Wojnar, Andrzej; Lesniak, Tadeusz; Zygulska, J.; Jantner, D.; Chudyba, Ewa; Zegarski, Wojciech; Las-Jankowska, Manuela; Jankowski, Michał; Kołodziejski, L; Radkowski, A.; Żelazowska-Omiotek, U.; Czeremszynska, B.; Kępka, Lucyna; Kołb-Sielecki, Jarosław; Toczko, Z.; Fedorowicz, Zbys; Dziki, Adam; Danek, Anna; Nawrocki, G; Sopyło, Rafał; Markiewicz, W.; Kędzierawski, Piotr; Wydmański, Jerzy

doi:10.1093/annonc/mdw062

Cited by 368 publications

(327 citation statements)

References 24 publications

Supporting

Mentioning

278

Contrasting

Unclassified

Order By: Relevance

“…The groups showed no differences in the rate of complete resection (R0), pathologic complete response, postoperative complications, local failure, or distant metastasis. However, in the short-course group, the acute toxicity rate was significantly lower, and os was improved 44 . Results from the ongoing rapido trial are awaited to provide additional information about this new approach 45 .…”

Section: Evidence Summarymentioning

confidence: 83%

Eastern Canadian Colorectal Cancer Consensus Conference 2017

et al. 2018

View full text Add to dashboard Cite

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including ■ identification and management of hereditary gastric and colorectal cancer (crc); ■ palliative systemic therapy for metastatic gastric cancer; ■ optimum duration of preoperative radiation in rectal cancer-that is, short-compared with long-course radiation; ■ management options for peritoneal carcinomatosis in crc; ■ implications of tumour location for treatment and prognosis in crc; and ■ new molecular markers in crc.

show abstract

Section: Evidence Summarymentioning

confidence: 83%

Eastern Canadian Colorectal Cancer Consensus Conference 2017

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Neuere [994]. Eine weitere randomisierte Phase-III-Studie (RAPIDO) testete bei MRT-definierten Hochrisikopatienten (T4, mrCRM+, N2, EMVI+) die Kurzzeit-Radiotherapie mit 5 × 5 Gy, gefolgt von 6 Zyklen CAPOX und Operation in Woche 22 -24 vs. einer konventionellen Radiochemotherapie mit Capecitabine und Operation in Woche 14 -16 [996].…”

Section: Konsensunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

148

View full text Add to dashboard Cite

“…[40] Bujko et al revealed no differences in local efficacy between both arms but reported an improved overall survival and lower acute toxicity for the 5×5 Gy schedule with consolidation chemotherapy. [40] Turk…”

Section: Evolution Of Preoperative Radiotherapymentioning

confidence: 96%

Where Should Radiotherapy Stand in the Current era of Rectal Cancer Management?

Sezen¹

2018

TJ Oncol

View full text Add to dashboard Cite

SUMMARYRectal cancer management can be defined as maximizing local tumor control and overall survival while preserving anal sphincter, bladder, and sexual functions or improving the quality of life with an overall reduction in morbidity. Appropriate preoperative or postoperative therapy is required to minimize the risks of both local and distant recurrence. Preoperative radiotherapy is the current standard for treating patients with high-risk rectal cancer owing to lower rates of local relapse and toxicity. Modern radiotherapy capabilities are well suited for any short-or long-course protocol with decreased toxicity in irradiated structures such as the small intestine, bladder, or femoral heads. As clinicians and researchers, we must aim to establish tailored treatments for these patients based on the most suitable evidence based ground in a multidisciplinary environment regarding the expectations of both our patients and team physicians. Herein, we present a review of ongoing clinical trials in order to shed light on the current debates of standard approaches for treating rectal cancer.

show abstract

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

Cited by 368 publications

References 24 publications

Eastern Canadian Colorectal Cancer Consensus Conference 2017

Eastern Canadian Colorectal Cancer Consensus Conference 2017

S3-Leitlinie – Kolorektales Karzinom

Where Should Radiotherapy Stand in the Current era of Rectal Cancer Management?

Contact Info

Product

Resources

About